<DOC>
	<DOCNO>NCT00003111</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy irinotecan cisplatin follow surgery treating patient stage IIIA non-small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Surgery Treating Patients With Stage IIIA Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate efficacy irinotecan base chemotherapy patient stage IIIA non-small cell lung cancer . - Investigate phenotypic change induce tumor treatment . OUTLINE : Patients receive IV cisplatin 30 minute follow IV irinotecan 30 minute day 1 , 8 , 15 , 22 . Treatment repeat every 6 week 3 course disease progression . Once potential candidate resectability determine , patient undergo thoracotomy concurrent chemotherapy/radiation therapy within 6 week complete last course chemotherapy . Following resection , patient respond chemotherapy receive 3 additional course IV carboplatin paclitaxel 3 hour . Patients may undergo local irradiation begin second course carboplatin paclitaxel . Chemotherapy cease disease remain stable 8 week . Patients follow every 3 month first year treatment , every 6 month thereafter survival . PROJECTED ACCRUAL : This study accrue 20 patient 18 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm , previously untreated stage IIIa ( T12 N2 M0 ) nonsmall cell lung cancer PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Total bilirubin great 1.5 mg/dL Renal : Creatinine clearance least 55 mL/min Other : Not HIV positive No active infection Not pregnant lactate Effective contraception require fertile patient study participation No coexist medical condition PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiation therapy No concurrent radiation therapy Surgery : Not specify Other : No concurrent use investigational agent study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
</DOC>